Promising Results Shown for CRISPR in Clinical Studies

Promising Results Shown for CRISPR

Promising Results Shown for CRISPR CRISPR has shown promising results in preliminary clinical studies to correct sickle cell disease and treat blindness, transthyretin amyloidosis, and hereditary angioedema. A new study in collaboration with University College London and Great Ormond Street Hospital for Children investigated the potential feasibility of base-edited CD7-targeted chimeric antigen receptor (BE-CAR7) T […]

Intracellular delivery of protein drugs

Intracellular Delivery of Protein Drugs

Intracellular Delivery of Protein Drugs Intracellular protein delivery is a daunting task that is near impossible due to the size and surface charge of proteins. However, protein macromolecule delivery is used in numerous disease states, such as monoclonal antibody therapeutics for cancer, autoimmune diseases, or asthma as well as the delivery of recombinant insulin to […]

How brain inflammation and healing is pointing to new glioblastoma targets

Canadian researchers have discovered that the healing process after a brain injury can give rise to the deadly brain tumor glioblastoma. By digging further to better understand that phenomenon, they’ve uncovered potential techniques for treating glioblastoma with precision medicine. Researchers from the University of Toronto, Hospital for Sick Children and the Princess Margaret Cancer Centre […]


ZURICH (Reuters) – Swiss drugmaker Novartis said on Saturday that its investigational spartalizumab immuno-oncology drug mixed with the approved medicines Tafinlar and Mekinist failed in a late-stage trial for a type of advanced skin cancer. The drug did not improve progression-free survival in previously untreated patients with BRAF V600 mutation-positive cutaneous melanoma, compared to Tafinlar […]

Partnered and backed by AbbVie, but cancer I-O biotech Tizona targeted by Gilead

Headed up by Scott Clarke, an ex-Roche exec who served as its global head of oncology partnering for Asia and emerging markets, the cancer immunotherapy company is working on several early assets, including TTX-030, a CD39-targeting antibody that last year attracted AbbVie’s interest and, according to preclinical data, seems to block an immune-inhibiting pathway in […]

Imvax Inc. Raises $112 Million in Series C Financing

Imvax Inc. Raises $112 Million in Series C Financing Funds to support Phase 2 Clinical Development of IGV-001 for treatment of Glioblastoma multiforme,  Phase 1 research into additional solid tumor indications and build out of the operational capabilities PHILADELPHIA, JULY 16, 2020 – Imvax, Inc., a clinical-stage biotechnology company whose groundbreaking personalized neo-antigen immunotherapy, IGV-001, is being […]